Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
77°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Virpax Pharmaceuticals Inc
(NQ:
VRPX
)
1.510
+0.440 (+41.12%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Virpax Pharmaceuticals Inc
< Previous
1
2
3
Next >
Virpax Announces Positive Results of Swine Model Pilot Study for Probudur™
July 10, 2024
From
Virpax Pharmaceuticals
Via
Business Wire
Virpax Pharmaceuticals Secures $2.5 Million Loan Financing and an Agreement with an Institutional Investor to Negotiate Additional Funding
July 08, 2024
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax® Pharmaceuticals to Present at 2024 BIO International Convention
May 29, 2024
From
Virpax Pharmaceuticals
Via
Business Wire
Virpax Announces Pricing of $2.25 Million Public Offering
May 15, 2024
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Pharmaceuticals Reports 2024 First Quarter Results and Recent Developments
May 13, 2024
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Announces Results of Maximum Tolerated Dose Study for Probudur™
April 30, 2024
From
Virpax Pharmaceuticals
Via
Business Wire
Virpax Pharmaceuticals Reports 2023 Year-End Results
March 26, 2024
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price
February 27, 2024
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.
February 27, 2024
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical Research
February 07, 2024
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Pharmaceuticals Announces Results of Special Shareholders Meeting
December 29, 2023
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing
November 17, 2023
From
Virpax Pharmaceuticals
Via
Business Wire
Virpax Pharmaceuticals Announces Leadership Transition
November 17, 2023
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Pharmaceuticals Reports 2023 Third Quarter Results and Recent Developments
November 15, 2023
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Pharmaceuticals Announces that Envelta™ Remains on Track for Trial in Humans Following FDA Review
October 31, 2023
From
Virpax Pharmaceuticals
Via
Business Wire
Virpax Pharmaceuticals Announces Extension of CRADA with the U.S. Army Institute of Surgical Research
October 12, 2023
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Gerald W. Bruce Appointed President and CEO of Novvae™ Pharmaceuticals
October 02, 2023
From
Virpax Pharmaceuticals
Via
Business Wire
Virpax Pharmaceuticals Announces Results of Probudur™ Dose Escalation Studies
September 27, 2023
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Pharmaceuticals to Present at the LD Micro Main Event XVI
September 26, 2023
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Altasciences Chosen by Virpax to Support the Development of a New Drug to Prevent Spread of Flu-like Viruses
September 21, 2023
From
Altasciences
Via
Business Wire
Virpax Pharmaceuticals Announces the Formation of Novvae™ Pharmaceuticals
September 18, 2023
From
Virpax Pharmaceuticals
Via
Business Wire
Virpax Pharmaceuticals Updates on Litigation
September 05, 2023
From
Virpax Pharmaceuticals
Via
Business Wire
Virpax® Pharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference
August 28, 2023
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Pharmaceuticals Reports 2023 Second Quarter Results and Recent Developments
August 14, 2023
From
Virpax® Pharmaceuticals, Inc.
Via
Business Wire
Virpax Pharmaceuticals Files Provisional Patent Application for NSAID Formulation and Method
August 10, 2023
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Pharmaceuticals, Inc. to Ring NASDAQ Closing Bell on July 24, 2023
July 24, 2023
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Pharmaceuticals Files Provisional Patent Application for Intranasal Delivery
July 13, 2023
From
Virpax Pharmaceuticals
Via
Business Wire
Virpax Pharmaceuticals Enters into CRADA with the National Advisory Neurological Disorders and Stroke Council
June 21, 2023
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
Virpax Pharmaceuticals Announces CFO Transition
June 20, 2023
From
Virpax Pharmaceuticals
Via
Business Wire
Virpax Pharmaceuticals to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
June 13, 2023
From
Virpax Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.